REGULATIONS OF ORPHAN DRUGS IN USA, EU AND INDIA-A COMPARATIVE STUDY
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 3
Abstract
Orphan drugs are the drugs and natural products used in treatment, diagnosis, or prevention of rare disease. The orphan drug regulation varies in different countries. Initially a guideline (Orphan Drug Act) for orphan drugs has been made in the USA. Exemption from application filing fees, tax credits for clinical research, marketing exclusivity for definite period of time and grant for phase I/II clinical trials are among the benefits given to the manufacturer of orphan drugs. As a result of these benefits number of drugs for the treatment of rare disease has been increased significantly in the last few decades. The orphan drug program can help the pharmaceutical companies in earning profit and recovering their investment even with small patient population in the developed countries. In 2001 a conference was held by the Indian Drugs Manufactures Association (IDMA) where a group of pharmacologists requested the Indian Government to establish the Orphan Drug Act in India. Indian rare disease population depends on developed countries approved orphan drugs because regulation for the orphan drugs has not been made by the Indian government. Developing countries are also feeling they should do something to promote the research and manufacturing of orphan drugs. The scarcity of regulation of orphan drugs adversely affects the economic growth of Indian medicinal industries. The present study reviews the orphan drug regulations in US, EU and India and raises some of the recent issues concerned to their regulation. .
Authors and Affiliations
Budhwar Vikaas, Singh Ajay K, Choudhary Manjusha
Keywords
Related Articles
- EP ID EP337030
- DOI 10.22270/ijdra.v4i3.187
- Views 104
- Downloads 0
PROBIOTIC FUNCTIONAL FOOD VS DRUGS: IMPACT OF INDIAN REGULATORY STATUS ON DESIGN OF QUALITY CONTROL GUIDLINES FOR PROBIOTICS
Probiotic now a day's generally utilized all around the globe because of headway as a part of the relationship in the middle of nourishment and wellbeing other than their promising helpful advantages and irrelevant react...
STEVIA AN UNTOUCHED NATURE’S GIFT CAN BE A BOON TO DIABETIC
Plants and fungi are a vital part of healthcare. Over 80% of the global population rely on traditional medicine, much of which is based on plant remedies. Traditional Chinese medicine alone uses over 5,000 plant species....
TECHNOLOGY DVELOPMENT FOR POLYMER MODIFICATION TO ENHANCE SOLUBILITY OF POORLY SOLUBLE DRUG
Solubilization of poorly soluble drugs is a frequently encountered challenge in screening studies of new chemical entities as well as in formulation design and development. Solubility of some drugs is very less; these dr...
Regulatory requirements for the approval of Anti-Cancer drug (Mercaptopurine) in Myanmar as per ACTD
South East Asian pharmaceutical market is growing rapidly. In Asian country, the regulatory environment is similar among all countries. But still requirements and process of registration is varying among countries of Asi...
ADVANCES IN THE REVIEW OF GENERIC DRUG APPLICATIONS BY UNITED STATES FOOD AND DRUG ADMINISTRATION, A REGULATORY PERSPECTIVE IN THE ERA OF GDUFA (GENERIC DRUG USER FEE AMENDMENT 2012)
A regulatory process, by which a person/organization/sponsor/innovator gets authorization to launch a drug in the market, is known as drug approval process. The United States - Food and Drug Administration (U.S. FDA) has...